TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06046378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Story Group Prepared With Digital Audio File (Podcast)
Description: The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
Study: NCT05919498

Intervention type: OTHER
Intervention: Individual semi-directive interview
Description: This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour.

Intervention type: OTHER
Intervention: Individual semi-directive interview
Description: This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour.

Intervention type: OTHER
Intervention: Focus groups
Description: This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours.

Intervention type: OTHER
Intervention: Focus groups
Description: This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours.
Study: NCT05664529

Intervention type: DIAGNOSTIC_TEST
Intervention: Chatoor Feeding Scale
Description: Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
Study: NCT05974176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused CBT (TF-CBT)
Description: TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems therapy (TST)
Description: Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
Study: NCT06231264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acustimulation at treatment sites
Description: A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electrical acustimulation at sham sites
Description: A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
Study: NCT06526429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
Study: NCT06563817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
Study: NCT05925465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary and mandibular nerve block
Description: receive bilateral combined maxillary and mandibular nerve block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: not receive any nerve block
Study: NCT05254808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
Study: NCT06504303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed socket
Description: During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
Study: NCT04855591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of SHR-1703 will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of SHR-1703 will be administered subcutaneously
Study: NCT05700396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Survivor Education Program
Description: Weekly sessions via Zoom platform with study staff.
Study: NCT05822674

Intervention type: DRUG
Intervention: Sitagliptin/metformin ( 50/500mg) Oral Tablet
Description: The drug was prescribed once daily per oral for 10 weeks

Intervention type: DRUG
Intervention: Empagliflozin/metformin(10/500mg) Oral Tablet
Description: The drug was prescribed once daily per oral for 10 weeks
Study: NCT05254808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
Study: NCT05089955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambient Experience
Description: MRI examination with Ambient Experience
Study: NCT05317624

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
Study: NCT04745884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bilateral monitoring of ICP waveform
Description: Brain4care non-invasive bilateral monitoring of ICP waveform
Study: NCT06201442

Intervention type: OTHER
Intervention: Imaging - magnetic resonance imaging (MRI)
Description: MRI knee - not standard of care

Intervention type: OTHER
Intervention: Imaging - magnetic resonance imaging (MRI)
Description: MRI knee - not standard of care

Intervention type: OTHER
Intervention: Blood sampling
Description: blood sample taken and analysis - not standard of care

Intervention type: OTHER
Intervention: Blood sampling
Description: blood sample taken and analysis - not standard of care

Intervention type: OTHER
Intervention: Assessment of functionality and strength
Description: Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care

Intervention type: OTHER
Intervention: Assessment of functionality and strength
Description: Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care

Intervention type: OTHER
Intervention: Activity monitoring
Description: Actigraph measurement- not standard of care

Intervention type: OTHER
Intervention: Activity monitoring
Description: Actigraph measurement- not standard of care

Intervention type: OTHER
Intervention: Imaging - x-ray scan (RX)
Description: RX Knee and EOS radiography full leg - not standard of care

Intervention type: OTHER
Intervention: Imaging - x-ray scan (RX)
Description: RX Knee and EOS radiography full leg - not standard of care

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Patient reported outcomes (PROMS)

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Patient reported outcomes (PROMS)
Study: NCT06327009

Intervention type: BEHAVIORAL
Intervention: fasting month of ramadan
Description: 100 patients with glomerulonephritis who decided to fast month of ramadan
Study: NCT06419335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
Study: NCT05255211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: IV before procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: IV before procedure
Study: NCT05915819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
Study: NCT05657288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist
Description: Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
Study: NCT05615597

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Para-discal injection of corticoid
Description: In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
Study: NCT05255211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: IV before procedure
Study: NCT06308263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774 [14C]M1774 microtracer
Description: Participants will receive single oral dose of M1774 containing a \[14C\]M1774 microtracer solution on day 1 of period 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: Participants will receive a single oral dose of M1774 on Day 1 of Period 1, and daily single oral dose of M1774 for 2 weeks in 21 days cycle of Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: Participants will receive a single oral dose of M1774 on Day 1 of Period 1, and daily single oral dose of M1774 for 2 weeks in 21 days cycle of Period 2.
Study: NCT04475276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lifestyle modification with placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alphalipoic acid
Description: Lifestyle modification with Alphalipoic acid for 12 weeks
Study: NCT05683860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
Study: NCT04857151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App based mindfulness program (ABMP)
Description: App based mindfulness program (ABMP)
Study: NCT05811819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment using the MyHand System
Description: Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
Study: NCT05607563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009 injection
Description: Participants receive PM1009 intravenously, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009 injection
Description: Participants receive PM1009 intravenously, every 2 weeks
Study: NCT05254418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulaglutide injection
Description: All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
Study: NCT05887336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Walther System
Description: Walther System providing INMEST treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Walther System
Description: Walther System not providing INMEST treatment, but otherwise behave as the active comparator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non preserved ocular lubricants
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Non preserved ocular lubricants
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eye lid procedure
Description: Lid hygiene, warm eye bag, lid massage and Omega 3

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Eye lid procedure
Description: Lid hygiene, warm eye bag, lid massage and Omega 3
Study: NCT06131112

Intervention type: DIAGNOSTIC_TEST
Intervention: 64Cu-DOTATATE PET/CT scan
Description: Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: 64Cu-DOTATATE PET/CT scan
Description: Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: 64Cu-DOTATATE PET/CT scan
Description: Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
Study: NCT06489249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate 750 MG Oral Tablet [DISALCID]
Description: Oral salsalate tablet
Study: NCT05913739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: Nocturnal oxygen therapy minimum 6 hours